-
Teva and Pfizer Settle Generic Neurontin Litigation
Tuesday, May 31, 2011 - 2:04pm | 91Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) announced today that patent litigation with Pfizer Inc. related to generic versions of Pfizer's (NYSE: PFE) Neurontin capsules and tablets sold by Teva and its subsidiary IVAX Pharmaceuticals has been dismissed by the United States District Court...
-
VIVUS Announces Additional Data From QNEXA Clinical Trials Presented at the European Congress on Obesity
Tuesday, May 31, 2011 - 11:06am | 133VIVUS, Inc. (NASDAQ: VVUS) today announced that multiple abstracts were presented over the weekend at the European Congress on Obesity in Istanbul, Turkey. A poster presentation authored by W. Timothy Garvey, MD from the University of Alabama at Birmingham reported reductions in progression to...
-
Market Roundup
Tuesday, May 31, 2011 - 10:46am | 292Shares of Ashland Inc (NYSE: ASH) jumped about 10% after the company announced its plans to buy specialty chemical maker International Specialty Products Inc for around $3.2 billion in cash. The deal is expected to close before the end of the fourth quarter and is likely to be immediately accretive...
-
Benzinga's Volume Movers
Tuesday, May 31, 2011 - 10:42am | 186Optimer Pharmaceuticals Inc (NASDAQ: OPTR) shares surged 7.24% to $13.92 at 10:40 am. The volume of OPTR shares traded was 815% higher than normal. The US Food and Drug Administration (FDA) has approved its antibacterial drug Dificid to treat Clostridium difficile. The Medicines Company (NASDAQ:...
-
Options Brief: Optimer Pharmaceuticals, Inc.
Tuesday, May 31, 2011 - 10:33am | 78Shares of Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) are higher on the session by 6.51%, trading at $13.82. Overall call volume is now running at 2.90x the daily average, with 67% of all calls traded being purchases on the offer. 7,581 contracts have traded on the session so far. Optimer...
-
NASDAQ Stocks Hitting 52-Week Highs
Tuesday, May 31, 2011 - 10:26am | 177BJ's Restaurants Inc (NASDAQ: BJRI) shares gained 2.23% to create a new 52-week high of $51.33. BJRI had $48.06 million in total cash and no debt for the latest quarter. Star Scientific Inc (NASDAQ: CIGX) shares jumped 6.23% to create a new 52-week high of $5.27. CIGX shares have surged 224.18%...
-
Bank of America Reiterates Buy on Pfizer
Tuesday, May 31, 2011 - 8:54am | 98Bank of America reiterated its Buy rating on Pfizer (NYSE: PFE). In a research report published today, Bank of America states, "Pfizer offers compelling valuation, an attractive dividend yield, and the potential for the ongoing strategic review to lead to actions that could enhance shareholder...
-
Jefferies Maintains Buy on Amarin
Tuesday, May 31, 2011 - 8:37am | 100Jefferies is out with its report today on Amarin (NASDAQ: AMRN), maintaining Buy. In a note to clients, Jefferies writes, "We had an opportunity to spend time with AMRN senior management to discuss potential scenarios for a pharma partnership or acquisition, AMR101 regulatory filings, and the CV...
-
Credit Suisse's Estimates and Price Target Changes
Tuesday, May 31, 2011 - 8:33am | 779Credit Suisse made a number of estimates and price target changes in a research report published today. BG Group plc (BRGYY) had its price target cut to 1,690p from 1,710p. At the moment, Credit Suisse has an outperform rating on the company's stock. In the report Credit Suisse states, "In this...
-
Jefferies Comments on Pfizer's JAK Inhibitor
Tuesday, May 31, 2011 - 8:32am | 93Jefferies is providing some comments on Pfizer's (NYSE: PFE) JAK inhibitor, tofacitinib. “Oral targeted disease modifying Rheumatoid Arthritis (RA) treatments were the hot topic at this year's European League Against Rheumatism (EULAR) annual meeting, last week (May 25-28),” Jefferies writes. “...
-
Benzinga's Top Pre-Market NASDAQ Gainers
Tuesday, May 31, 2011 - 8:12am | 160Optimer Pharmaceuticals Inc (NASDAQ: OPTR) shares advanced 7.86% to $14 in the pre-market session. OPTR reported that the US Food and Drug Administration (FDA) has approved its antibacterial drug Dificid to treat Clostridium difficile. The Medicines Company (NASDAQ: MDCO) shares advanced 4.24% to...
-
Citi Maintains Buy on Endo Pharmaceuticals Holdings
Tuesday, May 31, 2011 - 8:05am | 170Citi is out with its report today on Endo Pharmaceuticals Holdings (NASDAQ: ENDP), maintaining Buy. In a note to clients, Citi writes, "We rate the shares of Endo as Buy/High Risk (1H). We expect Lidoderm and the Opana/Opana ER franchise to continue to generate material cash flows for several...
-
Citigroup Reports on Pfizer
Tuesday, May 31, 2011 - 7:53am | 257Citigroup commented on Pfizer (NYSE: PFE) in a report released Monday. Citigroup was neutral in its assessment of the company. Citigroup writes, "PFE presented in-line data from its ORAL Sync tofacitinib (TOFA) Ph-III trial in rheumatoid arthritis (RA), & a Ph-II Lipitor combination study at...
-
Citigroup Reports on Forest Laboratories
Tuesday, May 31, 2011 - 7:48am | 148Citigroup commented on Forest Laboratories (NYSE: FRX) in a report released today. In the report, Citigroup was mixed in its assessment of the company. Citigroup writes, "Daliresp Launched in Mid-May at $5.47/day. Daliresp is the 1st oral 1x/day tab approved for exacerbations of COPD. We expect...
-
Jefferies Maintains DIFICID Sales Estimates
Tuesday, May 31, 2011 - 7:18am | 146Jefferies is maintaining its “modest/below-consensus sales estimates” on DIFICID, a new treatment for Clostridium difficileassociated diarrhea from Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR). “We maintain our U.S. sales estimates of ~$8M in 2011 (vs. consensus of ~$10M), ~$46M in 2012 (cons. ~$...